L'Oréal announces the planned acquisition of the La Roche-Posay spa company

L'Oréal has made an irrevocable offer to the shareholders of Holding STRP (Société des Thermes de La Roche-Posay) to acquire all the company's shares. The proposal provides for the prior sale of the hotel business to the current shareholders of Holding STRP, and exclusive negotiating rights for L'Oréal.
Founded in 1921, STRP is Europe's first spa dedicated exclusively to dermatological conditions. La Roche-Posay thermal spring water has anti-inflammatory, healing and soothing therapeutic properties, for the treatment of skin disorders (eczema, psoriasis, scarring after burns, cutaneous after-effects of cancer treatments). In 2017, the spa business benefited over 7,500 patients a year, generating sales of 3.6 million euros.
Laetitia Toupet, General Manager of La Roche-Posay, said: "This acquisition project will enable us to perpetuate and strengthen the dermatological roots of the La Roche-Posay brand by developing existing indications, and to make the spa the flagship of the brand".
Recommended by over 90,000 dermatologists worldwide, the La Roche-Posay brand creates skin care products formulated with thermal spring water for sensitive skin. The world's leading dermocosmetics brand, its main ranges are Lipikar (dry skin), Anthélios (photoprotection), Effaclar (acne-prone skin), Tolériane (sensitive skin) and Cicaplast (skin repair).
This project will be the subject of an information-consultation process with the employee representative bodies concerned, and should then be finalized in the coming months.